Latest Breaking News On - Salubris pharmaceutical co - Page 1 : comparemela.com

Final Phase 1b/2 data showing promising and durable signal of efficacy for Nana-val in patients with relapsed/refractory Epstein-Barr virus-positive (EBV+).

United statesIvor roystonAshleigh barretoSilicon valley bankShenzhen salubris pharmaceutical coExchange traded funds etfsDrug administrationAmerican society of hematologySunesis pharmaceuticalsViracta therapeutics incSalubris pharmaceutical coFinal phaseViracta therapeuticsChief executive officerT cell lymphomaAngioimmunoblastict cell